

Studies on Design and Evaluation of Sustained Released Microparticles

Rutuja Tukaram Khedkar, Prof. Komal A. Dongare, Dr. Surwase K. P
Aditya Institute of Pharmaceutical, Beed

Abstract: Sustained release microparticles are advanced drug delivery systems designed to release drugs at a controlled rate over an extended period, thereby improving therapeutic efficacy, reducing dosing frequency, and enhancing patient compliance. The present study focuses on the design, formulation, and evaluation of sustained release microparticles using suitable polymers and microencapsulation techniques. Various methods such as solvent evaporation, spray drying, and ionotropic gelation are commonly employed for the preparation of microparticles depending on the nature of the drug and polymer. Biodegradable and biocompatible polymers like PLGA, ethyl cellulose, Eudragit, and xanthan gum play an important role in controlling drug release behavior. The prepared microparticles were evaluated for physicochemical characteristics including particle size, surface morphology, percentage yield, drug entrapment efficiency, flow properties, and compatibility studies using techniques such as FTIR, DSC, and SEM. In vitro drug release studies were carried out to determine the sustained release pattern and release kinetics. The optimized formulations showed satisfactory entrapment efficiency, uniform particle distribution, and prolonged drug release over several hours following zero-order, Higuchi, or Korsmeyer–Peppas kinetic models.

Keywords: Sustained Release, Microparticles, Controlled Drug Delivery, Microencapsulation, Release Kinetics, Polymer Matrix, Drug.

I. INTRODUCTION

Sustained release microparticles are an important advancement in modern pharmaceutical drug delivery systems. These are small spherical particles, generally ranging from 1 μm to 1000 μm in size, designed to release a drug slowly and continuously over an extended period of time. The main objective of sustained release systems is to maintain a constant therapeutic concentration of the drug in the bloodstream for a prolonged duration, thereby reducing the frequency of administration and improving patient compliance. Microparticles are prepared using natural or synthetic polymers that encapsulate the active pharmaceutical ingredient and control its release rate. Depending on their structure, microparticles may exist as microspheres, where the drug is uniformly dispersed throughout the polymer matrix, or microcapsules, where the drug is enclosed within a polymeric shell. These systems help overcome the limitations of conventional dosage forms such as frequent dosing, fluctuating plasma drug levels, reduced bioavailability, and increased side effects. Sustained release microparticles offer several advantages including improved therapeutic efficacy, minimized drug toxicity, enhanced stability of drugs, and better patient convenience. They are widely used for oral, parenteral, topical, and targeted drug delivery applications.

Various techniques such as solvent evaporation, spray drying, coacervation, and ionotropic gelation are commonly employed for the preparation of microparticles. The evaluation of sustained release microparticles involves characterization parameters such as particle size, surface morphology, percentage yield, drug entrapment efficiency, flow properties, and in vitro drug release studies. Release kinetics are further analyzed using mathematical models to understand the mechanism of drug release.

Due to their ability to provide controlled and prolonged drug action, sustained release microparticles have gained significant importance in pharmaceutical research and development and continue to play a vital role in






Figure 1.1

1.1 Principle of Sustained Release Microparticles

Sustained release microparticles are small polymeric particles designed to release a drug slowly over an extended period of time. The main principle is to maintain a constant therapeutic concentration of the drug in the body for a prolonged duration while reducing the frequency of dosing and minimizing side effects.

Basic Principle

The drug is entrapped, dissolved, dispersed, or encapsulated within a polymer matrix or coating. After administration, the drug is released gradually by one or more controlled mechanisms such as diffusion, dissolution, erosion, or swelling of the polymer.

1.2 Mechanisms of Drug Release :

1. Diffusion-Controlled Release

The drug diffuses slowly through the polymer membrane or matrix into the surrounding biological fluid.

2. Dissolution-Controlled Release

The polymer or drug dissolves slowly in body fluids, leading to gradual drug release.

3. Erosion-Controlled Release

The polymer matrix erodes or degrades over time, releasing the entrapped drug.

4. Swelling-Controlled Release

Hydrophilic polymers absorb water, swell, and allow the drug to diffuse slowly.

Components of Sustained Release Microparticles Drug – active pharmaceutical ingredient Polymer – controls the release rate Solvent – used during preparation

Stabilizer/Surfactant – improves particle formation and stability

A Modified Drug Release System (MDRS) is a dosage form designed to alter the timing, rate, or place of drug release compared with conventional formulations. One important type is the Sustained Release Microparticle System, where tiny polymeric particles gradually release the drug over an extended period.



1.3 Sustained Release Microparticles

Microparticles are small spherical particles, generally ranging from 1–1000 μm , made from biodegradable or non-biodegradable polymers that encapsulate a drug and release it slowly.



Types of Microparticles

Microspheres – Drug uniformly dispersed within the polymer matrix.



Microcapsules – Drug surrounded by a distinct polymer coating.

Fig 1.2

1.4 Sustained Drug Delivery Systems:

Sustained release microparticles are a type of multi-particulate sustained drug delivery system. They combine the principles of SRDDS with the advantages of microparticle technology.

1. Why Microparticles for Sustained Release

Conventional single-unit SR tablets have risks: if the tablet fails, the entire dose dumps at once. Microparticles solve this because they are multi-unit systems. After oral intake, hundreds of microparticles spread in the GIT.

Failure

of a few particles does not cause dose dumping. This makes them safer and more reliable.

Key reasons for using microparticles as SRDDS:

1. Reduced inter/intra subject variability: Drug absorption is less affected by gastric emptying because subunits spread widely
2. Lower risk of dose dumping: No single large matrix to fail
3. Flexible dosing: Capsules can be opened and microparticles sprinkled on food for pediatric/geriatric use
4. Blend of release profiles: Fast and slow releasing microparticles can be mixed in one capsule to achieve initial + maintenance effect.




How SRDDS Principles Apply to Microparticles

Sustained release from microparticles is achieved by controlling drug diffusion, dissolution, or erosion through polymers. The mechanisms are same as SR tablets but applied at micron level. Mechanism How it works in microparticles Controlling factor Example Polymer
 Diffusion controlled Drug diffuses through polymer matrix or coat of each microsphere Polymer permeability, coat thickness Ethyl cellulose, Eudragit RS
 Dissolution controlled Polymer or drug dissolves slowly from surface Polymer


1.5 Methods of Preparation of Sustained Release Microparticles

Sustained release microparticles are prepared using different techniques depending on the drug properties, polymer type, desired particle size, and release characteristics.






CHEMICAL METHOD



1. EMULSION POLYMERIZATION :




2. INTERFACIAL POLYMERIZATION









4. PHASE SEPARATION/ COACERVATION METHOD




5. SPRAY DRYING METHOD



6. FLUIDIZED BED COATING:



7. CONTROLLED COATING:



1.6 History and Development of Sustained Release Microparticles

Introduction

Sustained release microparticles are small particulate drug delivery systems designed to release drugs slowly over an extended period. These systems improve therapeutic efficacy, reduce dosing frequency, minimize side effects, and enhance patient compliance. Microparticles are generally prepared using biodegradable or non-biodegradable polymers and are widely used in pharmaceutical formulations.

Historical Background

Early Drug Delivery Systems

The concept of controlled and sustained drug delivery began in the 1950s and 1960s when conventional dosage forms showed limitations such as:

Frequent dosing

Fluctuation in plasma drug concentration Poor patient compliance

Increased side effects

Researchers started developing systems capable of releasing drugs at predetermined rates for prolonged durations.

Emergence of Sustained Release Technology

During the 1960s and 1970s, polymer science expanded rapidly. Scientists discovered that polymers could be used to encapsulate drugs and regulate their release. This led to the development of:

Matrix tablets Reservoir systems

Microcapsules and microspheres

Microparticles became important because they offered:

Better drug protection

1.7 polymers

Polymers used in sustained-release microparticles are chosen based on how they control drug diffusion, degradation, swelling, and biocompatibility. These polymers are broadly classified into biodegradable and non-biodegradable types.

Poly(lactic-co-glycolic acid)

Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable aliphatic polyester synthesized by copolymerizing lactic acid and glycolic acid. It is one of the most studied and clinically used biodegradable polymers, valued for its tunable degradation, biocompatibility, and approval by major regulatory agencies for medical applications.

Key facts

- Chemical type: Aliphatic copolyester of lactic and glycolic acids
- Typical LA:GA ratios: 50:50 to 85:15
- Glass transition temperature: 45 - 55 ° C
- Degradation products: Lactic acid and glycolic acid (metabolized to CO₂ and H₂O)
- Common uses: Drug delivery systems, sutures, tissue scaffolds

Structure and synthesis

PLGA is formed through ring-opening polymerization or direct polycondensation of lactic acid (LA) and glycolic acid (GA). The relative ratio of the two monomers determines its crystallinity, hydrophobicity, and degradation rate: higher glycolic content accelerates hydrolysis. PLGA is usually amorphous, soluble in organic solvents such as dichloromethane or acetone, and its mechanical strength can be tailored by molecular-weight control.



Degradation mechanism

PLGA degrades mainly by hydrolytic cleavage of ester bonds, producing soluble oligomers and ultimately LA and GA. Hydrolysis proceeds faster in amorphous regions and is influenced by pH, molecular weight, and monomer ratio. At a 50:50

1.8 Drug Profile

Drug Profile of Sustained Release Microparticles

Introduction

Sustained release microparticles are small polymeric particles designed to release a drug slowly over an extended period of time. These systems improve therapeutic efficacy, reduce dosing frequency, minimize side effects, and maintain constant plasma drug concentration.

The “drug profile” refers to the physicochemical and pharmacokinetic characteristics of drugs that make them suitable for formulation into sustained release microparticles.

Ideal Drug Profile for Sustained Release Microparticles

1. Biological Half-Life

Drugs with a short biological half-life are most suitable for sustained release formulations.

Ideal half-life: 2–6 hours

Very short half-life drugs require frequent dosing and benefit from sustained release systems.

Examples Theophylline Propranolol Diclofenac

2. Dose Size

The drug should possess a moderate dose. Ideal dose: less than 500 mg

High-dose drugs are difficult to encapsulate into microparticles. Suitable Drugs

Ibuprofen Nifedipine

1.9 Polymer Profile

Polymer Profile of Sustained Release Microparticles Introduction

Polymers play an important role in the formulation of sustained release microparticles. They control the rate of drug release, improve stability, enhance encapsulation efficiency, and determine the physical characteristics of microparticles. Selection of an appropriate polymer is essential for obtaining desired sustained release action.

Ideal Properties of Polymers Used in Sustained Release Microparticles

An ideal polymer should possess the following properties:

1. Biocompatible
2. Biodegradable or non-toxic
3. Chemically stable
4. Good film-forming property
5. Controlled permeability
6. Compatible with drug
7. Easy to process
8. Economical and readily available

Classification of Polymers

1. Natural Polymers : Gelatin, Chitosan, Albumin, Starch.
2. Synthetic Polymer : Ethyl cellulose, Polylactarprolactone, Polyvinyl alcohol



Commonly Used Polymers in Sustained Released Microparticles.



Fig.1.2

1. Ethyl cellulose.

Use = oral sustained released formulations, microencapsulation.

2. Eudragit .

Use = Enteric coating, sustained released formulations.



Fig 1.s

3. Chitosan.

Use = Nasal and oral formulations, controlled drug delivery.






Fig 1.5

4. Gelatin

Use = Microencapsulation, Protein drug delivery Advantages = biocompatible, non-toxic.

5. PLGA (Poly Lactic-Co-Glycolic Acid)

Use = Injectable depot systems, sustained release formulation.

Factors Affecting Polymer Selection

- Drug compatibility
- Desired release rate
- Route of administration
- Drug stability
- Polymer biodegradability



1.10 Literature Review

Introduction

Sustained release microparticles are multiparticulate drug delivery systems designed to release drugs gradually over an extended period. These systems improve therapeutic efficacy, reduce dosing frequency, minimize adverse effects, and enhance patient compliance. Considerable research has focused on biodegradable polymeric microparticles, especially poly(lactic-co-glycolic acid) (PLGA)-based systems, because of their controlled release properties and biocompatibility.

Historical Background

Conventional dosage forms often produce rapid drug release and fluctuations in plasma drug concentration. To overcome these limitations, sustained release microparticles were developed to maintain therapeutic drug levels for prolonged periods. Early studies demonstrated that polymeric microparticles could effectively encapsulate drugs and provide controlled release through diffusion and polymer degradation mechanisms.

Role of Polymers in Sustained Release Microparticles Synthetic Polymers

Synthetic biodegradable polymers are widely used because they provide predictable drug release and controlled degradation.

Common Synthetic Polymers Poly(lactic-co-glycolic acid) (PLGA) Poly lactic acid (PLA) Polycaprolactone (PCL) Eudragit polymers

PLGA is the most extensively investigated polymer due to: Excellent biodegradability

Biocompatibility Regulatory approval

Adjustable degradation rate

Researchers reported that changing the lactic acid:glycolic acid ratio significantly alters the release profile and degradation characteristics of PLGA microparticles.

Natural Polymers

Natural polymers are also widely investigated because of their safety and biodegradability.

Examples Chitosan Gelatin Alginate Starch

Studies showed that natural polymers improve mucoadhesion and reduce toxicity while maintaining sustained release characteristics.

Preparation Methods Reported in Literature

1. Solvent Evaporation Method

The solvent evaporation technique is one of the most commonly used methods for preparing sustained release microparticles.

4. Advanced Preparation Techniques

Recent literature highlights several advanced technologies: Microfluidics

Electrospray methods Supercritical fluid technology

Nanoparticles-in-microparticles systems These methods improve:

Particle size uniformity Drug loading

Controlled release properties Reproducibility

Advanced fabrication approaches also reduce burst release problems. Drug Release Mechanism

Drug release from sustained release microparticles mainly occurs through: Drug diffusion

II. CONCLUSION

The present project on “Studies on Design and Evaluation of Sustained Release Microparticles” successfully highlights the importance of sustained release drug delivery systems in modern pharmaceutical science. Sustained release microparticles have emerged as an advanced and effective approach for controlling the release of drugs over an extended period of time. These systems provide several therapeutic, pharmacokinetic, and patient-related advantages



when compared with conventional dosage forms. The study demonstrates that the design and evaluation of sustained release microparticles involve a careful understanding of polymers, drug properties, preparation methods, and evaluation parameters to achieve the desired therapeutic outcome.

Microparticles are small spherical particles generally ranging from 1 μm to 1000 μm in diameter and are prepared using natural or synthetic polymers. In sustained release systems, the drug is either encapsulated within or dispersed throughout the polymeric matrix. The polymer acts as a release-retarding material that controls the diffusion and degradation process of the drug. The project emphasizes that proper selection of polymer plays a major role in determining drug release characteristics, encapsulation efficiency, particle stability, and therapeutic performance. Natural polymers such as chitosan, gelatin, sodium alginate, and starch provide biocompatibility and biodegradability, while synthetic polymers such as PLGA, ethyl cellulose, Eudragit, and polycaprolactone offer better mechanical strength and controlled release properties.

The study also concludes that sustained release microparticles improve therapeutic efficacy by maintaining drug concentration within the therapeutic range for prolonged periods. Conventional dosage forms often produce fluctuations in plasma drug concentration, resulting in frequent dosing and reduced patient compliance. Sustained release microparticles overcome these limitations by releasing the drug slowly and continuously, thereby reducing dose frequency and minimizing side effects associated with peak plasma concentrations. This controlled drug release profile enhances patient convenience, improves adherence to therapy, and ensures better disease management, especially in chronic conditions requiring long-term medication.

Different methods of preparation discussed in the project, such as phase separation coacervation, solvent evaporation, spray drying, emulsion cross-linking, ionic gelation, and solvent extraction techniques, demonstrate the versatility of microparticle technology. Among these methods, phase separation coacervation was found to be one of the most widely used and effective methods for preparing sustained release microparticles due to its simplicity, high drug loading capacity, and ability to produce uniform particles. The preparation method selected depends upon the nature of the sustained release microparticle systems. Researchers are exploring smart polymers, biodegradable carriers, mucoadhesive systems, and stimuli-responsive drug delivery systems to achieve better therapeutic control.

Combination approaches involving microparticles with nanoparticles, liposomes, and hydrogels are also being investigated to improve drug targeting and release efficiency. Future developments in this field are expected to provide safer, more effective, and patient-friendly drug delivery systems.

In conclusion, the project successfully demonstrates that sustained release microparticles are highly effective drug delivery systems capable of improving therapeutic efficacy, patient compliance, and controlled drug release. Proper formulation design, suitable polymer selection, optimized preparation methods, and thorough evaluation studies are essential for developing successful sustained release microparticle formulations. These systems represent an important advancement in pharmaceutical technology and have a promising future in the treatment of various acute and chronic diseases.

Sustained release microparticles continue to play a significant role in the development of innovative and efficient drug delivery systems, thereby contributing greatly to the advancement of modern healthcare and pharmaceutical sciences.

REFERENCES

1. Controlled Drug Delivery: Fundamentals and Applications
Robinson JR, Lee VHL. Controlled Drug Delivery: Fundamentals and Applications. 2nd ed. New York: Marcel Dekker; 2005
2. Modern Pharmaceutics Banker GS, Rhodes CT. Modern Pharmaceutics. 4th ed. New York: Marcel Dekker; 2002.
3. Remington: The Science and Practice of Pharmacy
Gennaro AR. Remington: The Science and Practice of Pharmacy. 21st ed. Philadelphia: Lippincott Williams & Wilkins; 2006.



4. Pharmaceuticals: The Science of Dosage Form Design Aulton ME. Pharmaceuticals: The Science of Dosage Form Design. 2nd ed. London: Churchill Livingstone; 2002.
5. Theory and Practice of Industrial Pharmacy Lachman L, Lieberman HA, Kanig JL. Theory and Practice of Industrial Pharmacy. 3rd ed. Mumbai: Varghese Publishing House; 2009.
6. Biopharmaceutics and Pharmacokinetics Notari RE. Biopharmaceutics and Pharmacokinetics: An Introduction. 4th ed. New York: Marcel Dekker; 1992.
7. Novel Drug Delivery Systems Chien YW. Novel Drug Delivery Systems. 2nd ed. New York: Marcel Dekker; 1992.
8. Encyclopedia of Pharmaceutical Technology Swarbrick J, Boylan JC. Encyclopedia of Pharmaceutical Technology. 3rd edition, New York: Informa Healthcare; 2007.
9. Pharmaceutical Microencapsulation

